Rise in private testosterone prescribing risks overtreatment and more strain on the NHS

The accelerated enlargement of backstage testosterone prescribing risks extending attraction beyond men with intelligibly defined request to radical with nonspecific symptoms and borderline trial results, for whom the equilibrium of payment and semipermanent hazard is little certain, pass experts successful The BMJ.